Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07497399 · ClinicalTrials.gov registry record · Phase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
A Phase 2 study, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT07497399: Recruiting Phase 2 study, sponsored by Johns Hopkins University.
NCT07497399 is a Phase 2 study that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07497399, a Phase 2 study, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI). Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).
Interventions
- DRUG Placebo
- DRUG NLY01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-04-28 |
| Est. Completion | 2030-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07497399
The ClinicalTrials.gov registry entry for NCT07497399 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07497399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07497399 about?
NCT07497399 is a clinical study titled "Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis". The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measur...
What is the current status of trial NCT07497399?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-04-28. Estimated completion is 2030-01.
What interventions are being tested in trial NCT07497399?
The interventions under investigation include: Placebo (DRUG), NLY01 (DRUG).
Who is sponsoring clinical trial NCT07497399?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.